liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Intraperitoneal Chemotherapy of Ovarian Cancer
Linköping University, Department of Biomedicine and Surgery, Oncology. Linköping University, Faculty of Health Sciences.
1993 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Ovarian cancer is still the most common cause of death among gynecologic malignancies in spite of the fact that newer and more effective drugs and/or administration techniques have been developed in the last decade. However, substantial improvements in response rate andprogression-free survival have been reported in many studies.

In this study the efficacy, toxicity and feasibility of different drugs administered IP were evaluated in patients with ovarian cancer. The maximum tolerated dose of carboplatin administered IP was determined to be 500 mg!m2 This dose was given adjuvantly in a phase IT study to 47 women with early-stage disease. There were 10 patients in this study who developed recurrent disease. The toxicity was acceptable, the major dose-limiting toxic effect being hematologic, especially thrombocytopenia. One patient developed grade 3 nephrotoxicity after the second course. There was no incidence of treatment-related death.

Thirty-five patients with advanced ovarian cancer were treated with an aggressive combination regimen (cisplatin/etoposide) intraperitoneally with IV sodium thiosulphate as antidote. The dose-limiting toxic effect was hematologic. Two patients developed severe nephrotoxicity. The median progression-free interval was 13 months and the survival at closing point 31% with a median follow-up of 16 months.

The patient acceptance and feasibility of using subcutaneously implantable peritoneal access devices were analyzed in 125 patients. Port-A-Cath was used in 98% of the patients, 465 IP courses were administered and 27 (21.6%) severe or moderate complications related to Port-A-Cath were registered.

The incidence of nephrotoxicity in patients treated IP with platinum-containing regimens was analysed. Six of 135 patients (4%) developed severe nephrotoxicity; impairment of renal function, as judged by serum creatinine, was seen in most patients. This was cumulative during treatment and not completely reversible. Young age was a predictive factor for severe nephrotoxicity.

Place, publisher, year, edition, pages
Edsbruk: Akademitryck AB , 1993. , 62 p.
Linköping University Medical Dissertations, ISSN 0345-0082 ; 376
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-25689Local ID: 10065ISBN: 91-7870-917-2OAI: diva2:246237
Public defence
1993-02-19, Onkologens föreläsningssal, Universitetssjukhuset, Linköping, 13:00 (Swedish)
Papers, included in the Ph.D. thesis, are not registered and included in the posts from 1999 and backwards.Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2012-07-23Bibliographically approved

Open Access in DiVA

No full text

By organisation
OncologyFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 1324 hits
ReferencesLink to record
Permanent link

Direct link